CIBC Asset Management
CORT icon

CIBC Asset Management’s Corcept Therapeutics CORT Stock Holding History

CIBC Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,340
Closed -$278K – 1377
2025
Q3 		$278K Hold
3,340
– – ﹤0.01% 966
2025
Q2 		$245K Hold
3,340
– – ﹤0.01% 987
2025
Q1 		$381K Buy
+3,340
New +$203K ﹤0.01% 793
2024
Q4 		– Sell
-5,214
Closed -$241K – 1235
2024
Q3 		$241K Buy
+5,214
New +$185K ﹤0.01% 986

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC Asset Management's CORT Position: Q4 2025 in Review

CIBC Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 3,340 shares — an estimated $278K sold.

CIBC Asset Management first reported a position in CORT in Q3 2024 and held it in 4 quarters. The position peaked at $381K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • CIBC Asset Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • CIBC Asset Management sold 3,340 Corcept Therapeutics shares in Q4 2025, an estimated $278K.
  • CIBC Asset Management first reported a position in Corcept Therapeutics in Q3 2024 and held it in 4 quarters.
  • CIBC Asset Management's Corcept Therapeutics position peaked at $381K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on CIBC Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.